Open access
Open access
Powered by Google Translator Translator

RCT | Dipeptidyl peptidase-1 inhibition does not improve outcomes in patients hospitalized with COVID-19.

13 Sep, 2022 | 13:15h | UTC

Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial – The Lancet Respiratory Medicine

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.